Long term treatment of endometriosis associated pain (EAP) with linzagolix: Efficacy and safety after 12 months of treatment
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Percentages of women experiencing a reduction of ≥30% in both dysmenorrhea and non-menstrual pelvic pain at week 52 were 69.2% and 69.2% in the linzagolix 75 mg group, 69.2% and 53.8% in the 100 mg group, and 64.7% and 76.5% in the 200/100 mg group.
“Percentages of women experiencing a reduction of ≥30% in both dysmenorrhea and non-menstrual pelvic pain at week 52 were respectively 69.2% and 69.2% in the 75 mg group, 69.2% and 53.8% in the 100 mg group and 64.7 % and 76.5% in the 200/100 mg group.”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [113]
Percentages of women with a ≥30% reduction in overall pelvic pain at week 52 were 69.2%, 53.8% and 82.4% in the linzagolix 75 mg, 100 mg and 200/100 mg groups.
“Percentages of women with a ≥30% reduction in overall pelvic pain (OPP) (primary efficacy endpoint) at week 52 were 69.2%, 53.8% and 82.4% in the 75 mg, 100 mg and 200/100 mg groups, respectively.”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [113]
Mean percentage (95% CI) BMD changes in the lumbar spine were −1.14 (−2.21 −0.07) at linzagolix 75 mg, −1.40 (−3.35 +0.55) at 100 mg and −2.19 (−3.59 −0.78) at 200/100 mg.
“Mean percentage (95% CI) BMD changes in the lumbar spine were −1.14 (−2.21 −0.07) at a dose of 75 mg, −1.40 (−3.35 +0.55) at a dose of 100 mg and −2.19 (−3.59 −0.78) at a dose of 200/100 mg.”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [113]
Response rates for overall pelvic pain, dysmenorrhea and non-menstrual pelvic pain were maintained or increased after 52 weeks of linzagolix treatment.
“Response rates for overall pelvic pain, dysmenorrhea and non-menstrual pelvic pain were maintained or increased after 52 weeks of treatment.”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [113]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
Donnez, J., & Dolmans, M.-M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051085 · Cited by 182 · see citing works
A Lifelong Impact on Endometriosis: Pathophysiology and Pharmacological Treatment
Chen, L.-H., Lo, W.-C., Huang, H.-Y., & Wu, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087503 · Cited by 85 · see citing works
Hormonal drugs for the treatment of endometriosis
Capezzuoli, T., Rossi, M., Torre, F. L., Vannuccini, S., & Petraglia, F. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102311 · Cited by 71 · see citing works
Dababou, S., Garzon, S., Laganà, A. S., Ferrero, S., Evangelisti, G., Noventa, M., D’Alterio, M. N., Palomba, S., Uccella, S., Franchi, M. P., et al. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1957830 · Cited by 65 · see citing works
“At 52 weeks, the pelvic pain, dysmenorrhea, and nonmenstrual pain responders were 69% in the 75 mg group and 82%, 65%, and 76% in the 200/100 mg group [8,41].”
BackgroundDonnez, J., & Dolmans, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111342 · Cited by 49 · see citing works
“Hot flushes were more frequent at higher doses of linzagolix [21,61].”
BackgroundKeam, S. J. (2022) · Drugs · doi:10.1007/s40265-022-01753-9 · Cited by 22 · see citing works
Viviano, M., Benagiano, G., Guo, S., & Pluchino, N. (2024) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2024.104321 · Cited by 17 · see citing works
Yarmolinskaya, M. I., Khachaturyan, A. R., Andreeva, N. Y., & Олеговна, П. В. (2020) · Russian Journal of Human Reproduction · doi:10.17116/repro20202605178 · Cited by 2 · see citing works
Lan, K., Cheng, Y.-H., Huang, C.-R., Weng, P.-L., Chang, Y.-C., & Cheng, J. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101024
- Authors
- Taylor, R. N., Bestel, E., Gotteland, J.-P., Lecomte, V., Dubouloz, R., Terrill, P., Humberstone, A., & Loumaye, E.
- Affiliations
- University of Utah (US)
- ObsEva (Switzerland) (CH)
- ORCID
- Taylor, Robert N.
- Venue
- Fertility and Sterility
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 112
- Issue
- 3
- Pages
- e323
- ISSN
- 0015-0282 (ISSN-L)
- OpenAlex
- W2975434972
- Cited by
- 9
- References
- 0
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 1
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Fertility and Sterility (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Menstrual Health and Disorders
- Keywords
- endometriosis-associated pain, linzagolix, GnRH antagonist, long-term efficacy, safety, bone mineral loss, dysmenorrhea, non-menstrual pelvic pain, dyspareunia, dyschezia, dose-response relationship
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
